This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Minshall M, St. Charles M, Pandya B, Baran RW.The cost-effectiveness of pioglitazone compared with rosiglitazone: an economic evaluation projecting results from a clinical study into the future using a valid and reliable economic model from a third party payer perspective in the USA. Value in Health 10: A259 (plus poster) abstr. PDB18, No. 6, Nov-Dec 2007
Minshall M, St. Charles M, Pandya B, Baran RW, Bron M.The cost-effectiveness of pioglitazone compared with sitagliptin: an economic evaluation using a validted economic model from a third party payer perspective in the USA. Value in Health 10: A259 (plus poster) abstr. PDB19, No. 6, Nov-Dec 2007
Lloyd AC, Twena N, Townsend C, Holman AJ.Costs and neonatal outcomes after insulin aspart compared with human insulin in pregnant women with type 1 diabetes. Value in Health 10: A262 (plus poster) abstr. PDB26, No. 6, Nov-Dec 2007
Rights and permissions
About this article
Cite this article
Pioglitazone pays dividends in type 2 diabetes mellitus. Pharmacoecon. Outcomes News 540, 3–4 (2007). https://doi.org/10.2165/00151234-200705400-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705400-00002